165 related articles for article (PubMed ID: 30168015)
21. Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.
Anderson AM; Lennox JL; Mulligan MM; Loring DW; Zetterberg H; Blennow K; Kessing C; Koneru R; Easley K; Tyor WR
J Neurovirol; 2017 Feb; 23(1):106-112. PubMed ID: 27400930
[TBL] [Abstract][Full Text] [Related]
22. Plasma and cerebrospinal fluid human immunodeficiency virus type-1 (HIV-1) RNA levels in HIV-related cognitive impairment.
Stankoff B; Calvez V; Suarez S; Bossi P; Rosenblum O; Conquy L; Turell E; Dubard T; Coutellier A; Baril L; Bricaire F; Lacomblez L; Lubetzki C
Eur J Neurol; 1999 Nov; 6(6):669-75. PubMed ID: 10529754
[TBL] [Abstract][Full Text] [Related]
23. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.
Coban H; Robertson K; Smurzynski M; Krishnan S; Wu K; Bosch RJ; Collier AC; Ellis RJ
AIDS; 2017 Jul; 31(11):1565-1571. PubMed ID: 28471765
[TBL] [Abstract][Full Text] [Related]
24. The association between physical activity and cognition in men with and without HIV infection.
Monroe AK; Zhang L; Jacobson LP; Plankey MW; Brown TT; Miller EN; Martin E; Becker JT; Levine AJ; Ragin A; Sacktor NC
HIV Med; 2017 Sep; 18(8):555-563. PubMed ID: 28294530
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors.
De Ronchi D; Faranca I; Berardi D; Scudellari P; Borderi M; Manfredi R; Fratiglioni L
Arch Neurol; 2002 May; 59(5):812-8. PubMed ID: 12020265
[TBL] [Abstract][Full Text] [Related]
26. An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China.
Zhang Y; Qiao L; Ding W; Wei F; Zhao Q; Wang X; Shi Y; Li N; Smith D; Chen D
J Neurovirol; 2012 Apr; 18(2):120-6. PubMed ID: 22411002
[TBL] [Abstract][Full Text] [Related]
27. (1→3)-β-D-Glucan Levels Correlate With Neurocognitive Functioning in HIV-Infected Persons on Suppressive Antiretroviral Therapy: A Cohort Study.
Hoenigl M; de Oliveira MF; Pérez-Santiago J; Zhang Y; Morris S; McCutchan AJ; Finkelman M; Marcotte TD; Ellis RJ; Gianella S
Medicine (Baltimore); 2016 Mar; 95(11):e3162. PubMed ID: 26986173
[TBL] [Abstract][Full Text] [Related]
28. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
[TBL] [Abstract][Full Text] [Related]
29. Preliminary study of a novel cognitive assessment device for the evaluation of HIV-associated neurocognitive impairment.
Anderson AM; Lennox JL; Nguyen ML; Waldrop-Valverde D; Tyor WR; Loring DW
J Neurovirol; 2016 Dec; 22(6):816-822. PubMed ID: 27245594
[TBL] [Abstract][Full Text] [Related]
30. Normative scores for select neuropsychological battery tests for the detection of HIV-associated neurocognitive disorder amongst Nigerians.
Nweke M; Mshunqane N; Govender N; Akinpelu AO; Ogunniyi A
Niger Postgrad Med J; 2022; 29(3):262-267. PubMed ID: 35900464
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of HIV-Associated Neurocognitive Disorder (HAND) among Patients Attending a Tertiary Health Facility in Northern Nigeria.
Yusuf AJ; Hassan A; Mamman AI; Muktar HM; Suleiman AM; Baiyewu O
J Int Assoc Provid AIDS Care; 2017; 16(1):48-55. PubMed ID: 25331222
[TBL] [Abstract][Full Text] [Related]
32. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people.
Vitiello B; Goodkin K; Ashtana D; Shapshak P; Atkinson JH; Heseltine PN; Eaton E; Heaton R; Lyman WD
AIDS; 2007 Jul; 21(11):1415-22. PubMed ID: 17589187
[TBL] [Abstract][Full Text] [Related]
34. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.
Kamat A; Lyons JL; Misra V; Uno H; Morgello S; Singer EJ; Gabuzda D
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):234-43. PubMed ID: 22569268
[TBL] [Abstract][Full Text] [Related]
35. Neurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation.
Airoldi M; Bandera A; Trabattoni D; Tagliabue B; Arosio B; Soria A; Rainone V; Lapadula G; Annoni G; Clerici M; Gori A
Clin Dev Immunol; 2012; 2012():467154. PubMed ID: 22489249
[TBL] [Abstract][Full Text] [Related]
36. Empiric neurocognitive performance profile discovery and interpretation in HIV infection.
Gomez D; Power C; Gill MJ; Koenig N; Vega R; Fujiwara E
J Neurovirol; 2019 Feb; 25(1):72-84. PubMed ID: 30519968
[TBL] [Abstract][Full Text] [Related]
37. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy.
Pérez-Valero I; González-Baeza A; Estébanez M; Montes-Ramírez ML; Bayón C; Pulido F; Bernardino JI; Zamora FX; Monge S; Gaya F; Lagarde M; Rubio R; Hernando A; Arnalich F; Arribas JR
PLoS One; 2013; 8(7):e69493. PubMed ID: 23936029
[TBL] [Abstract][Full Text] [Related]
38. Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.
Spudich S; Robertson KR; Bosch RJ; Gandhi RT; Cyktor JC; Mar H; Macatangay BJ; Lalama CM; Rinaldo C; Collier AC; Godfrey C; Eron JJ; McMahon D; Jacobs JL; Koontz D; Hogg E; Vecchio A; Mellors JW
J Clin Invest; 2019 Jul; 129(8):3339-3346. PubMed ID: 31305262
[TBL] [Abstract][Full Text] [Related]
39. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder.
McCutchan JA; Marquie-Beck JA; Fitzsimons CA; Letendre SL; Ellis RJ; Heaton RK; Wolfson T; Rosario D; Alexander TJ; Marra C; Ances BM; Grant I;
Neurology; 2012 Feb; 78(7):485-92. PubMed ID: 22330412
[TBL] [Abstract][Full Text] [Related]
40. Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients.
Ciccarelli N; Grima P; Fabbiani M; Baldonero E; Borghetti A; Milanini B; Limiti S; Colafigli M; Tamburrini E; Cauda R; De Luca A; Di Giambenedetto S
Antivir Ther; 2015; 20(4):433-40. PubMed ID: 25504667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
